- B2B
- Early StageStartup in initial stages
Perthera careers
Perthera offers a Precision Oncology Platform that uses multi-omic molecular testing results and each patient's past medical and treatment history to optimize treatment option matchmaking for cancer patients.
Perthera's Therapeutic Intelligence Engine, an advanced algorithm that combines machine learning and true AI, combines each patient's data to produce recommended treatment options utilizing the most current published clinical research and available clinical trials. The treatment options produced from the Therapeutic Intelligence Engine are then reviewed by a Virtual Molecular Tumor Board, staffed by cancer experts from top institutions across the country, for every patient.
The final product is a clinical report, which ranks treatment options in order based on strength of evidence for each patient's molecular and treatment data. This report provides a strong tool for oncologists to evaluate various viable treatment options and relevant clinical trials for their patients.
Perthera's Therapeutic Intelligence Engine, an advanced algorithm that combines machine learning and true AI, combines each patient's data to produce recommended treatment options utilizing the most current published clinical research and available clinical trials. The treatment options produced from the Therapeutic Intelligence Engine are then reviewed by a Virtual Molecular Tumor Board, staffed by cancer experts from top institutions across the country, for every patient.
The final product is a clinical report, which ranks treatment options in order based on strength of evidence for each patient's molecular and treatment data. This report provides a strong tool for oncologists to evaluate various viable treatment options and relevant clinical trials for their patients.
Perthera hasn't added any jobs yet
Get notified when Perthera posts new jobs.
Gary Gregory
CEO of Perthera, with 30 years in the Healthcare Sector. Leadership roles across successful start-up companies and Fortune 250 companies (J&J, Baxter)
Valuation
$0
Funded over
1 round
Latest round
Series A (Jun 2016)
NTT Data • Halifax • 1 month ago
Teva Pharmaceutical Industries • Cincinnati • 1 month ago
BLN24 • McLean • 1 month ago
Maximus • United States • 1 month ago
Emerald Therapeutics • Austin • 1 month ago
